We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Clovis Oncology incurred loss of 64 cents per share for the first quarter of 2021, narrower than the Zacks Consensus Estimate of a loss of 72 cents and the year-ago loss of $1.39 per share.
Net revenues, entirely from Clovis’ only marketed drug, Rubraca, were down 10.6% year over year to $38.1 million in the quarter, missing the Zacks Consensus Estimate of $44.8 million.
Shares of Clovis were up 6.4% on May 5, following first-quarter results. The stock has gained 22.1% so far this year against the industry’s decrease of 6%.
Quarter in Details
Sales of Rubraca, a PARP inhibitor, in the United States were $31.7 million, down 19.3% year over year. Product sales were down due to lower new patient starts amid the COVID-19 pandemic. However, the company expects sales to normalize starting from the second quarter and improve in the second half of 2021.
Ex-U.S. market sales were $6.4 million in the first quarter compared with $3.3 million in the year-ago quarter.
In the first quarter, research & development expenses decreased 23% year over year to $52.8 million, primarily due to lower spending on Rubraca clinical studies. Selling, general and administrative expenses declined 29.8% year over year to $29.9 million, driven by cost-saving initiatives and savings due to the COVID-19 situation globally.
Clovis ended the quarter with $190.9 million of cash equivalents and available-for-sale securities compared with $240.2 million as of Dec 31, 2020.
The company expects its cash resources, along with anticipated revenues and available financing sources, to be enough to support its operations till early 2023.
Update on Rubraca
The company has a collaboration with Bristol-Myers (BMY - Free Report) to develop Rubraca and pipeline candidate, lucitanib, in combination with the latter’s PD-L1 inhibitor, Opdivo, for several cancer indications. A phase III study — ATHENA — is evaluating Rubraca as a monotherapy as well as in combination with Opdivo as first-line maintenance treatment for advanced ovarian cancer. Top-line data from the monotherapy arm is expected in the second half of 2021. Interim data from phase II part of phase Ib/II LIO-1 study, evaluating lucitanib in combination with Opdivo as potential treatment for gynecologic cancers, is expected later this year.
A phase II LODESTAR study is evaluating Rubraca in patients with recurrent solid tumors associated with deleterious homologous recombination repair or HRR gene mutations. Data from the study may be used to file a regulatory application in the first half of 2022, seeking approval for Rubraca in HRR patients.
The company plans to initiate a phase I/II study — LuMIERE — in the second quarter of 2021 to evaluate its peptide-targeted radionuclide therapy and imaging agent candidate, FAP-2286, in multiple tumor types.
Clovis Oncology, Inc. Price, Consensus and EPS Surprise
Atea’s earnings per share estimates have moved up from $3.79 to $8.34 for 2021 and from $16.76 to $17.25 for 2022 in the past 30 days. The stock has soared 757.3% in the past year.
Nabriva’s loss per share estimates have narrowed from $2.03 to $1.95 for 2021 and from $1.35 to $1.22 in the past 30 days. The company delivered an earnings surprise of 46.50%, on average, in the last four quarters.
Zacks Top 10 Stocks for 2021
In addition to the stocks discussed above, would you like to know about our 10 best buy-and-hold tickers for the entirety of 2021?
Last year's 2020Zacks Top 10 Stocks portfolio returned gains as high as +386.8%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.
Image: Bigstock
Clovis (CLVS) Q1 Earnings Beat, COVID-19 Hurts Rubraca Sales
Clovis Oncology incurred loss of 64 cents per share for the first quarter of 2021, narrower than the Zacks Consensus Estimate of a loss of 72 cents and the year-ago loss of $1.39 per share.
Net revenues, entirely from Clovis’ only marketed drug, Rubraca, were down 10.6% year over year to $38.1 million in the quarter, missing the Zacks Consensus Estimate of $44.8 million.
Shares of Clovis were up 6.4% on May 5, following first-quarter results. The stock has gained 22.1% so far this year against the industry’s decrease of 6%.
Quarter in Details
Sales of Rubraca, a PARP inhibitor, in the United States were $31.7 million, down 19.3% year over year. Product sales were down due to lower new patient starts amid the COVID-19 pandemic. However, the company expects sales to normalize starting from the second quarter and improve in the second half of 2021.
Ex-U.S. market sales were $6.4 million in the first quarter compared with $3.3 million in the year-ago quarter.
In the first quarter, research & development expenses decreased 23% year over year to $52.8 million, primarily due to lower spending on Rubraca clinical studies. Selling, general and administrative expenses declined 29.8% year over year to $29.9 million, driven by cost-saving initiatives and savings due to the COVID-19 situation globally.
Clovis ended the quarter with $190.9 million of cash equivalents and available-for-sale securities compared with $240.2 million as of Dec 31, 2020.
The company expects its cash resources, along with anticipated revenues and available financing sources, to be enough to support its operations till early 2023.
Update on Rubraca
The company has a collaboration with Bristol-Myers (BMY - Free Report) to develop Rubraca and pipeline candidate, lucitanib, in combination with the latter’s PD-L1 inhibitor, Opdivo, for several cancer indications. A phase III study — ATHENA — is evaluating Rubraca as a monotherapy as well as in combination with Opdivo as first-line maintenance treatment for advanced ovarian cancer. Top-line data from the monotherapy arm is expected in the second half of 2021. Interim data from phase II part of phase Ib/II LIO-1 study, evaluating lucitanib in combination with Opdivo as potential treatment for gynecologic cancers, is expected later this year.
A phase II LODESTAR study is evaluating Rubraca in patients with recurrent solid tumors associated with deleterious homologous recombination repair or HRR gene mutations. Data from the study may be used to file a regulatory application in the first half of 2022, seeking approval for Rubraca in HRR patients.
The company plans to initiate a phase I/II study — LuMIERE — in the second quarter of 2021 to evaluate its peptide-targeted radionuclide therapy and imaging agent candidate, FAP-2286, in multiple tumor types.
Clovis Oncology, Inc. Price, Consensus and EPS Surprise
Clovis Oncology, Inc. price-consensus-eps-surprise-chart | Clovis Oncology, Inc. Quote
Zacks Rank & Stocks to Consider
Clovis currently has a Zacks Rank #3 (Hold).
Some better-ranked stocks from the drug/biotech sector include Atea Pharmaceuticals, Inc. (AVIR - Free Report) and Nabriva Therapeutics AG , both carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Atea’s earnings per share estimates have moved up from $3.79 to $8.34 for 2021 and from $16.76 to $17.25 for 2022 in the past 30 days. The stock has soared 757.3% in the past year.
Nabriva’s loss per share estimates have narrowed from $2.03 to $1.95 for 2021 and from $1.35 to $1.22 in the past 30 days. The company delivered an earnings surprise of 46.50%, on average, in the last four quarters.
Zacks Top 10 Stocks for 2021
In addition to the stocks discussed above, would you like to know about our 10 best buy-and-hold tickers for the entirety of 2021?
Last year's 2020Zacks Top 10 Stocks portfolio returned gains as high as +386.8%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.
AccessZacks Top 10 Stocks for 2021 today >>